非布索坦治疗痛风效果怎样？

Also known as Febuxostat, it was approved for marketing in 2013. Febuxostat inhibits uric acid production by inhibiting xanthine oxidase (XO). Allopurinol can inhibit the reduced form of XO, while febuxostat has a good inhibitory effect on both the reduced and oxidized forms, so its uric acid-lowering effect is more powerful and faster. Adult patients need to start taking this medicine from 10 mg, once a day, 10 mg once a day, and at the same time, the uric acid content in the body must be tested. After two weeks, the once-daily dosage can be increased to 20 mg, and after six weeks, the once-daily maintenance dosage can be increased to 40 mg, etc. Today we will find out how effective febuxostat is in treating gout patients.

A phase III study presented at the 72nd Annual Scientific Session of the American College of Rheumatology and the 43rd Annual Meeting of the American Association of Rheumatology Physicians (ACR/ARHP) showed that febuxostat 40 mg is as effective as allopurinol 300 mg in reducing urate in patients with gout.

In this study, a total of 2269 patients with gout (serum uric acid level ≥8.0 mg/dL at baseline) were randomized in a 1:1:1 ratio to receive febuxostat 40 mg, febuxostat 80 mg, or allopurinol 300 mg. Among these patients, 145 patients had moderate chronic kidney disease. The primary efficacy endpoint of the study was the percentage of all patients with a final serum uric acid level <6.0 mg/dL.

The study results showed that the percentages of patients in the febuxostat 40 mg, 80 mg, and allopurinol groups who achieved serum uric acid levels <6.0 mg/dL at 6 months were 45%, 67%, and 42%, respectively. The efficacy of reducing urate in the febuxostat 40 mg group was similar to that of the allopurinol group, but the efficacy of the febuxostat 80 mg group was better than that of the febuxostat 40 mg group and the allopurinol group (both comparisons were statistically significant). In an important subgroup of patients with unmet medical needs, namely patients with chronic kidney disease, febuxostat 80 mg was more effective in reducing urate (72%) than febuxostat 40 mg (50%) or allopurinol (42%); and in these patients, the 40 mg group was also more effective in reducing urate than allopurinol. In this study, the incidence of adverse events, including cardiovascular events, was similar across all groups.